サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1771577

米国の経腸栄養剤市場規模、シェア、動向分析レポート：製品別、フロータイプ別、ステージ別、適応症別、最終用途別、販売チャネル別、セグメント予測、2025年～2030年

U.S. Enteral Feeding Formulas Market Size, Share & Trends Analysis Report By Product, By Flow Type, By Stage, By Indication, By End use, By Sales Channel, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 90 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.47円
米国の経腸栄養剤市場規模、シェア、動向分析レポート：製品別、フロータイプ別、ステージ別、適応症別、最終用途別、販売チャネル別、セグメント予測、2025年～2030年
出版日: 2025年06月11日
発行: Grand View Research
ページ情報: 英文 90 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

市場規模と動向：

米国の経腸栄養剤市場規模は2024年に20億6,000万米ドルと推定され、2025年から2030年にかけてCAGR 5.7%で成長すると予測されます。

がん、脳卒中、多発性硬化症、認知症、慢性肝疾患、慢性閉塞性肺疾患（COPD）、糖尿病などの慢性疾患の有病率の増加により、経口摂取の課題に対応する製品の需要が増加すると予測されます。2024年5月に発表された米国疾病予防管理センター（CDC）の報告によると、米国では約3,840万人が糖尿病を患っており、これは全人口の約11.96%に相当します。

アルツハイマー病の有病率の増加は、経腸栄養剤の需要を押し上げています。進行期の患者はしばしば嚥下障害に直面し、栄養補給を必要とするからです。CDCによると、米国では約690万人がアルツハイマー病を患っています。さらに2022年には、米国成人の死亡原因の第7位、65歳以上の成人の死亡原因の第6位となっています。米国における高齢化人口の増加は、経腸栄養剤の需要を促進するもう一つの重要な要因です。高齢になると、食欲の減退、嚥下困難（嚥下障害）、消化効率の低下といった生理的な変化がしばしば見られ、適切に管理されなければ栄養失調につながります。経腸栄養は、高齢者、特に介護付き住宅または長期介護施設に居住する高齢者が十分な栄養摂取を確保するための実用的な解決策を提供します。

介護者やヘルスケア提供者の間で、高齢者ケアにおける早期栄養介入の重要性に対する認識が高まっていることが、経腸栄養製品の採用にさらに拍車をかけています。

早産児の増加は、新生児の栄養要件を満たすための経口栄養剤の需要を押し上げている重要な要因の1つです。2022年のCDCによると、早産は米国で生まれた乳児の約10人に1人に影響を及ぼしています。さらに、特に乳児や妊婦における微量栄養素、タンパク質、その他の栄養素の深刻な欠乏を含む栄養欠乏症やその他の欠乏症の継続的な増加が、経腸栄養用調製粉乳の需要増加につながっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場の変数、動向、範囲

  • 市場系統の見通し
  • テクノロジーの概要
  • 価格分析
  • 消費者行動分析
    • 採用パターン
    • 購買行動
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 業界の課題
  • ビジネス環境分析
    • ポーターのファイブフォース分析
    • PESTLE分析
    • COVID-19の影響

第4章 米国の経腸栄養剤市場：製品の推定・動向分析

  • セグメントダッシュボード
  • 経腸栄養剤市場：製品変動分析、2023年および2030年
    • 標準
    • 疾患

第5章 米国の経腸栄養剤市場：フロータイプの推定・動向分析

  • セグメントダッシュボード
  • 経腸栄養剤市場：フロータイプ変動分析、2023年および2030年
    • 間欠給餌フロー
    • 常用供給フロー

第6章 米国の経腸栄養剤市場：ステージの推定・動向分析

  • セグメントダッシュボード
  • 経腸栄養剤市場：ステージ変動分析、2023年および2030年
  • 成人
  • 小児

第7章 米国の経腸栄養剤市場：適応症の推定・動向分析

  • セグメントダッシュボード
  • 経腸栄養剤市場：適応症変動分析、2023年および2030年
  • アルツハイマー病
  • 栄養不足
    • がんケア
    • 糖尿病
    • 慢性腎臓病
    • 希少疾患
    • 嚥下障害
    • 疼痛管理
    • 吸収不良/消化管障害/下痢
    • その他

第8章 米国の経腸栄養剤市場：最終用途の推定・動向分析

  • セグメントダッシュボード
  • 経腸栄養剤市場：最終用途変動分析、2023年および2030年
    • 病院
    • ホームケア

第9章 米国の経腸栄養剤市場：販売チャネルの推定・動向分析

  • セグメントダッシュボード
  • 経腸栄養剤市場：販売チャネル変動分析、2023年および2030年
    • オンライン販売
    • 小売売上高
    • 機関投資家向け販売

第10章 競合情勢

  • 企業市場シェア分析、2024年（％）
  • 企業分類
  • 企業プロファイル/上場企業
    • Ajinomoto Cambrooke
    • Global Health Products, Inc.
    • Kate Farms
    • Abbott
    • Danone SA
    • Kabi AG
    • Nestle
    • Primus Pharmaceuticals, Inc.
    • Mead Johnson &Company, LLC
    • Alcresta Therapeutics
    • Real Food Blends
    • B. Braun SE
図表

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. U.S. Enteral feeding formulas market, Product, 2018 - 2030 (USD Million)
  • Table 4. U.S. Enteral feeding formulas market, by Flow Type, 2018 - 2030 (USD Million)
  • Table 5. U.S. Enteral feeding formulas market, by Stage, 2018 - 2030 (USD Million)
  • Table 6. U.S. Enteral feeding formulas market, by Indication, 2018 - 2030 (USD Million)
  • Table 7. U.S. Enteral feeding formulas market, by End Use, 2018 - 2030 (USD Million)
  • Table 8. U.S. Enteral feeding formulas market, by Sales Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Market segmentation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment snapshot
  • Fig. 10 Competitive landscape snapshot
  • Fig. 11 Market trends & outlook
  • Fig. 12 Market driver relevance analysis (current & future impact)
  • Fig. 13 Market restraint relevance analysis (current & future impact)
  • Fig. 14 PESTLE analysis
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 U.S. Enteral feeding formulas market: Products movement analysis
  • Fig. 17 U.S. Enteral feeding formulas market: Products outlook and key takeaways
  • Fig. 18 Standard Formula market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Disease-Specific Formulas market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Enteral feeding formulas market: Flow Type movement analysis
  • Fig. 21 U.S. Enteral feeding formulas market: Flow Type outlook and key takeaways
  • Fig. 22 Intermittent feeding flow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Continuous feeding flow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Enteral feeding formulas market: Stage movement analysis
  • Fig. 25 U.S. Enteral feeding formulas market: Stage outlook and key takeaways
  • Fig. 26 Adults market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Pediatrics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Enteral feeding formulas market: Indication movement analysis
  • Fig. 29 U.S. Enteral feeding formulas market: Indication outlook and key takeaways
  • Fig. 30 Alzheimer's market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Nutrition Deficiency market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Cancer Care market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Diabetes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Chronic Kidney Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Orphan Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Dysphagia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Pain Management market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Malabsorption/GI Disorder/Diarrhea market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 U.S. Enteral feeding formulas market: End Use movement analysis
  • Fig. 41 U.S. Enteral feeding formulas market: End Use outlook and key takeaways
  • Fig. 42 Cardiology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Neurology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Critical Care (ICU) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Home Care market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 U.S. Enteral feeding formulas market: Sales Channel movement analysis
  • Fig. 49 U.S. Enteral feeding formulas market: Sales Channel outlook and key takeaways
  • Fig. 50 Online sales market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 51 Retail sales market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Institutional sales market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 53 Market Participant Categorization
  • Fig. 54 Strategy mapping
  • Fig. 55 Company market position analysis
目次
Product Code: GVR-4-68040-613-4

Market Size & Trends:

The U.S. enteral feeding formulas market size was estimated at USD 2.06 billion in 2024 and is projected to grow at a CAGR of 5.7% from 2025 to 2030. The increasing prevalence of chronic diseases, including cancer, stroke, multiple sclerosis, dementia, chronic liver disease, chronic obstructive pulmonary disease (COPD), and diabetes, is anticipated to increase the demand for products addressing oral intake challenges. The Centers for Disease Control and Prevention (CDC) reports published in May 2024 states that approximately 38.4 million people in U.S. have diabetes, which is around 11.96% of the overall population.

The growing prevalence of Alzheimer's disease is boosting demand for enteral feeding formulas, as patients in advanced stages often face difficulty in swallowing and require nutritional support. According to the CDC, around 6.9 million people in the U.S. are living with Alzheimer's disease. Furthermore, in 2022, it was the 7th leading cause of death among U.S. adults and the 6th leading cause of death among adults 65 years or older. The rising aging population in the U.S. is another key factor driving the demand for enteral feeding formulas. As individuals age, they often experience physiological changes such as reduced appetite, swallowing difficulties (dysphagia), and decreased digestive efficiency, leading to malnutrition if not properly managed. Enteral feeding provides a practical solution to ensure adequate nutrient intake among elderly individuals, particularly those residing in assisted living or long-term care facilities.

Increased awareness among caregivers and healthcare providers regarding the importance of early nutritional intervention in geriatric care is further fueling the adoption of enteral nutrition products.

Rise in preterm births is one of the significant factors boosting the demand for sip feeds to meet the nutritional requirements of newborns. According to the CDC in 2022, preterm birth affected about 1 of every 10 infants born in the U.S. In addition, the continued rise in nutritional and other deficiencies, including severe deficiency of micronutrients, proteins, and other nutrients, especially in infants and pregnant women, is leading to an increase in the demand for enteral feeding formulas.

U.S. Enteral Feeding Formulas Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. enteral feeding formulas market report based on product, flow type, stage, indication, end use, and sales channel.

  • Product Outlook (Revenue, USD Million, 2018 - 2030)
  • Standard Formula
  • Disease-specific Formulas
  • Flow Type Outlook (Revenue, USD Million, 2018 - 2030)
  • Intermittent Feeding Flow
  • Continuous Feeding Flow
  • Stage Outlook (Revenue, USD Million, 2018 - 2030)
  • Adults
  • Pediatrics
  • Indication Outlook (Revenue, USD Million, 2018 - 2030)
  • Alzheimer's
  • Nutrition Deficiency
  • Cancer Care
  • Diabetes
  • Chronic Kidney Diseases
  • Orphan Diseases
  • Dysphagia
  • Pain Management
  • Malabsorption/GI Disorder/Diarrhea
  • Others
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Hospitals
    • Cardiology
    • Neurology
    • Critical Care (ICU)
    • Oncology
    • Others
  • Home Care
  • Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Online Sales
  • Retail Sales
  • Institutional Sales

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Flow Type
    • 1.2.3. Stage
    • 1.2.4. Indication
    • 1.2.5. End Use
    • 1.2.6. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Technology Overview
  • 3.3. Pricing Analysis
  • 3.4. Consumer Behavior Analysis
    • 3.4.1. Adoption Pattern
    • 3.4.2. Purchasing behaviors
  • 3.5. Market Dynamics
    • 3.5.1. Market Driver Analysis
      • 3.5.1.1. Rising geriatric population
      • 3.5.1.2. Growing prevalence of chronic diseases
      • 3.5.1.3. Shifting trend toward consumption of disease-specific formulas
      • 3.5.1.4. Growing demand for neonatal and preterm enteral feeding
    • 3.5.2. Market Restraint Analysis
      • 3.5.2.1. Lack of awareness in the medical community
      • 3.5.2.2. Improper categorization of clinical nutrition
    • 3.5.3. Market Opportunity Analysis
    • 3.5.4. Industry Challenges
      • 3.5.4.1. Complications associated with small-bore connectors
      • 3.5.4.2. Risks associated with enteral feeding
  • 3.6. Business Environment Analysis
    • 3.6.1. Porter's Five Forces Analysis
      • 3.6.1.1. Supplier power
      • 3.6.1.2. Buyer power
      • 3.6.1.3. Substitution threat
      • 3.6.1.4. Threat of new entrant
      • 3.6.1.5. Competitive rivalry
    • 3.6.2. PESTLE Analysis
      • 3.6.2.1. Political landscape
      • 3.6.2.2. Economic landscape
      • 3.6.2.3. Social landscape
      • 3.6.2.4. Technological landscape
      • 3.6.2.5. Environmental landscape
      • 3.6.2.6. Legal landscape
    • 3.6.3. Impact of COVID 19

Chapter 4. U.S. Enteral Feeding Formulas Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Enteral Feeding Formulas Market: Product Movement Analysis, 2023 & 2030 (USD Million)
    • 4.2.1. Standard formula
      • 4.2.1.1. Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Disease-specific formula
      • 4.2.2.1. Market Estimates and forecasts, 2018 - 2030(USD Million)

Chapter 5. U.S. Enteral Feeding Formulas Market: Flow Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Enteral Feeding Formulas Market: Flow Type Movement Analysis, 2023 & 2030 (USD Million)
    • 5.2.1. Intermittent Feeding Flow
      • 5.2.1.1. Market Estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Continuous Feeding Flow
      • 5.2.2.1. Market Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Enteral Feeding Formulas Market: Stage Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Enteral Feeding Formulas Market: Stage Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Adult
    • 6.3.1. Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 6.4. Pediatric
    • 6.4.1. Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Enteral Feeding Formulas Market: Indication Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Enteral Feeding Formulas Market: Indication Movement Analysis, 2023 & 2030 (USD Million)
  • 7.3. Alzheimer's Disease
    • 7.3.1. Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.4. Nutrition Deficiency
    • 7.4.1. Nutrition Deficiency, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Cancer Care
    • 7.4.3. Cancer Care, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Diabetes
    • 7.4.5. Diabetes, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. Chronic Kidney Diseases
    • 7.4.7. Chronic Kidney Diseases, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.8. Orphan Diseases
    • 7.4.9. Orphan Diseases, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.10. Dysphagia
    • 7.4.11. Dysphagia, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.12. Pain Management
    • 7.4.13. Pain Management, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.14. Malabsorption/GI Disorder/Diarrhea
    • 7.4.15. Malabsorption/Gi Disorder/Diarrhea, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.16. Others
    • 7.4.17. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. U.S. Enteral Feeding Formulas Market: End Use Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Enteral Feeding Formulas Market: End Use Movement Analysis, 2023 & 2030 (USD Million)
    • 8.2.1. Hospitals
      • 8.2.1.1. Hospitals Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
      • 8.2.1.1.1.Cardiology
          • 8.2.1.1.1.1. Cardiology Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
      • 8.2.1.1.2.Neurology
          • 8.2.1.1.2.1. Neurology, Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
      • 8.2.1.1.3.Critical Care (ICU)
          • 8.2.1.1.3.1. Critical Care (ICU) Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
      • 8.2.1.1.4.Oncology
          • 8.2.1.1.4.1. Oncology Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
      • 8.2.1.1.5.Others
          • 8.2.1.1.5.1. Others Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.2.2. Home Care
      • 8.2.2.1. Home Care Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9. U.S. Enteral Feeding Formulas Market: Sales Channel Estimates & Trend Analysis

  • 9.1. Segment Dashboard
  • 9.2. Enteral Feeding Formulas Market: Sales Channel Movement Analysis, 2023 & 2030 (USD Million)
    • 9.2.1. Online Sales
      • 9.2.1.1. Online Sales Market Revenue Estimates and forecasts, 2018 - 2030 (USD Million)
    • 9.2.2. Retail Sales
      • 9.2.2.1. Retail Sales Market Revenue Estimates and forecasts, 2018 - 2030
    • 9.2.3. Institutional Sales
      • 9.2.3.1. Institutional Sales Market Revenue Estimates and forecasts, 2018 - 2030

Chapter 10. Competitive Landscape

  • 10.1. Company Market Share Analysis, 2024 (%)
  • 10.2. Company Categorization
  • 10.3. Company Profiles/Listing
    • 10.3.1. Ajinomoto Cambrooke
      • 10.3.1.1. Overview
      • 10.3.1.2. Financial performance
      • 10.3.1.3. Product benchmarking
      • 10.3.1.4. Strategic initiatives
    • 10.3.2. Global Health Products, Inc.
      • 10.3.2.1. Overview
      • 10.3.2.2. Financial performance
      • 10.3.2.3. Product benchmarking
      • 10.3.2.4. Strategic initiatives
    • 10.3.3. Kate Farms
      • 10.3.3.1. Overview
      • 10.3.3.2. Financial performance
      • 10.3.3.3. Product benchmarking
      • 10.3.3.4. Strategic initiatives
    • 10.3.4. Abbott
      • 10.3.4.1. Overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Product benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Danone S.A
      • 10.3.5.1. Overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Product benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Kabi AG
      • 10.3.6.1. Overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Product benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. Nestle
      • 10.3.7.1. Overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Product benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Primus Pharmaceuticals, Inc.
      • 10.3.8.1. Overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Product benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Mead Johnson & Company, LLC
      • 10.3.9.1. Overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Product benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Alcresta Therapeutics
      • 10.3.10.1. Overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Product benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. Real Food Blends
      • 10.3.11.1. Overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Product benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. B. Braun SE
      • 10.3.12.1. Overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Product benchmarking
      • 10.3.12.4. Strategic initiatives